PRMT1 Integrates Immune Microenvironment and Fatty Acid Metabolism Response in Progression of Hepatocellular Carcinoma

References

• Kelley KR, Greten FT, Phimister EG. Hepatocellular carcinoma-origins and outcomes. N Engl J Med. 2021;385(3):280–282. doi:10.1056/NEJMcibr2106594
   PubMed Web of Science ®Google Scholar
• Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9(4):452–463. doi:10.21037/hbsn-20-480
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Zheng Y, Wang S, Cai J, Ke A, Fan J. The progress of immune checkpoint therapy in primary liver cancer. Biochim Biophys Acta Rev Cancer. 2021;1876(2):188638. doi:10.1016/j.bbcan.2021.188638
   PubMed Web of Science ®Google Scholar
• Wang J, Wang F, Wang N, Zhang MY, Wang HY, Huang GL. Diagnostic and prognostic value of protein post-translational modifications in hepatocellular carcinoma. J Clin Transl Hepatol. 2023;11(5):1192–1200. doi:10.14218/JCTH.2022.00006S
   PubMed Web of Science ®Google Scholar
• Peng C, Wong CC. The story of protein arginine methylation: characterization, regulation, and function. Expert Rev Proteomics. 2017;14(2):157–170. doi:10.1080/14789450.2017.1275573
   PubMed Web of Science ®Google Scholar
• Kaniskan HÜ, Konze KD, Jin J. Selective inhibitors of protein methyltransferases. J Med Chem. 2015;58(4):1596–1629. doi:10.1021/jm501234a
   PubMed Web of Science ®Google Scholar
• Jarrold J, Davies CC. PRMTs and arginine methylation: cancer’s best-kept secret? Trends Mol Med. 2019;25(11):993–1009. doi:10.1016/j.molmed.2019.05.007
   PubMed Web of Science ®Google Scholar
• Wu Q, Schapira M, Arrowsmith CH, Barsyte-Lovejoy D. Protein arginine methylation: from enigmatic functions to therapeutic targeting. Nat Rev Drug Discov. 2021;20(7):509–530. doi:10.1038/s41573-021-00159-8
   PubMed Web of Science ®Google Scholar
• Li X, Wang C, Jiang H, Luo C. A patent review of arginine methyltransferase inhibitors (2010–2018). Expert Opin Ther Pat. 2019;29(2):97–114. doi:10.1080/13543776.2019.1567711
   PubMed Web of Science ®Google Scholar
• Blanc RS, Richard S. Arginine methylation: the coming of age. Mol Cell. 2017;65(1):8–24. doi:10.1016/j.molcel.2016.11.003
   PubMed Web of Science ®Google Scholar
• Hwang JW, Cho Y, Bae GU, Kim SN, Kim YK. Protein arginine methyltransferases: promising targets for cancer therapy. Exp Mol Med. 2021;53(5):788–808. doi:10.1038/s12276-021-00613-y
   PubMed Web of Science ®Google Scholar
• Li Z, Wang D, Lu J, et al. Methylation of EZH2 by PRMT1 regulates its stability and promotes breast cancer metastasis. Cell Death Differ. 2020;27(12):3226–3242. doi:10.1038/s41418-020-00615-9
   PubMed Web of Science ®Google Scholar
• Li B, Liu L, Li X, Wu L. miR‐503 suppresses metastasis of hepatocellular carcinoma cell by targeting PRMT1. Biochem Biophys Res Commun. 2015;464(4):982–987. doi:10.1016/j.bbrc.2015.06.169
   PubMed Web of Science ®Google Scholar
• Zhao J, O’Neil M, Schonfeld M, Komatz A, Weinman SA, Tikhanovich I. Hepatocellular protein arginine methyltransferase 1 suppresses alcohol-induced hepatocellular carcinoma formation by inhibition of inducible nitric oxide synthase. Hepatol Commun. 2020;4(6):790–808. doi:10.1002/hep4.1488
   PubMed Web of Science ®Google Scholar
• Zhao J, O’Neil M, Vittal A, Weinman SA, Tikhanovich I. PRMT1-dependent macrophage IL-6 production is required for alcohol-induced HCC progression. Gene Expr. 2019;19(2):137–150. doi:10.3727/105221618X15372014086197
   PubMedGoogle Scholar
• Parry RV, Ward SG. Protein arginine methylation: a new handle on T lymphocytes? Trends Immunol. 2010;31(4):164–169. doi:10.1016/j.it.2010.01.006
   PubMed Web of Science ®Google Scholar
• Kim H, Kim H, Feng Y, et al. PRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity. Sci Transl Med. 2020;12(551):eaaz5683. doi:10.1126/scitranslmed.aaz5683
   PubMed Web of Science ®Google Scholar
• Srour N, Villarreal OD, Hardikar S, et al. PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade. Cell Rep. 2022;38(13):110582. doi:10.1016/j.celrep.2022.110582
   PubMed Web of Science ®Google Scholar
• Schonfeld M, Zhao J, Komatz A, Weinman SA, Tikhanovich I. The polymorphism rs975484 in the protein arginine methyltransferase 1 gene modulates expression of immune checkpoint genes in hepatocellular carcinoma. J Biol Chem. 2020;295(20):7126–7137. doi:10.1074/jbc.RA120.013401
   PubMed Web of Science ®Google Scholar
• Charlène T, Louisane E, Coralie P, Muriel LR. Structure, activity, and function of PRMT1. Life. 2021;11(11):1147. doi:10.3390/life11111147
   PubMedGoogle Scholar
• Xu J, Richard S. Cellular pathways influenced by protein arginine methylation: implications for cancer. Mol Cell. 2021;81(21):4357–4368. doi:10.1016/j.molcel.2021.09.011
   PubMed Web of Science ®Google Scholar
• Zhao Y, Lu Q, Li C, et al. PRMT1 regulates the tumour-initiating properties of esophageal squamous cell carcinoma through histone H4 arginine methylation coupled with transcriptional activation. Cell Death Dis. 2019;10(5):359. doi:10.1038/s41419-019-1595-0
   PubMedGoogle Scholar
• Liang Z, Liu L, Wen C, et al. Clinicopathological and prognostic significance of PRMT5 in cancers: a system review and meta-analysis. Cancer Control. 2021;28:107327482110505. doi:10.1177/10732748211050583
   Web of Science ®Google Scholar
• Lei X, Lei Y, Li JK, et al. Immune cells within the tumor microenvironment: biological functions and roles in cancer immunotherapy. Cancer Lett. 2020;470:126–133. doi:10.1016/j.canlet.2019.11.009
   PubMed Web of Science ®Google Scholar
• Kurebayashi Y, Ojima H, Tsujikawa H, et al. Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification. Hepatology. 2018;68(3):1025–1041. doi:10.1002/hep.29904
   PubMed Web of Science ®Google Scholar
• Infantino S, Light A, O’Donnell K, et al. Tarlinton D Arginine methylation catalyzed by PRMT1 is required for B cell activation and differentiation. Nat Commun. 2017;8(1):891. doi:10.1038/s41467-017-01009-1
   PubMedGoogle Scholar
• Luo Y, Gao Y, Liu W, et al. MYC-protein arginine methyltransferase 5 axis defines the tumorigenesis and immune response in hepatocellular carcinoma. Hepatology. 2021;74(4):1932–1951. doi:10.1002/hep.31864
   PubMed Web of Science ®Google Scholar
• Waidmann O. Recent developments with immunotherapy for hepatocellular carcinoma. Expert Opin Biol Ther. 2018;18(8):905–910. doi:10.1080/14712598.2018.1499722
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee JH, Lim YS, et al. Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up. Cancer Immunol Immunother. 2019;68(1):23–32. doi:10.1007/s00262-018-2247-4
   PubMed Web of Science ®Google Scholar
• Liu HT, Jiang MJ, Deng ZJ, et al. Immune checkpoint inhibitors in hepatocellular carcinoma: current progresses and challenges. Front Oncol. 2021;11:737497. doi:10.3389/fonc.2021.737497
   PubMedGoogle Scholar
• Calderaro J, Rousseau B, Amaddeo G, et al. Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features. Hepatology. 2016;64(6):2038–2046. doi:10.1002/hep.28710
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380. doi:10.1002/hep.29086
   PubMed Web of Science ®Google Scholar
• Zhou J, Sun H, Wang Z, et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 Edition). Liver Cancer. 2020;9(6):682–720. doi:10.1159/000509424
   PubMed Web of Science ®Google Scholar
• Sangro B, Gomez-Martin C, de la Mata M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013;59(1):81–88. doi:10.1016/j.jhep.2013.02.022
   PubMed Web of Science ®Google Scholar
• Lastwika KJ, Wilson W 3rd, Li QK, et al. Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer. Cancer Res. 2016;76(2):227–238. doi:10.1158/0008-5472.CAN-14-3362
   PubMed Web of Science ®Google Scholar
• Zheng NN, Zhou M, Sun F, et al. Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression. World J Gastroenterol. 2020;26(26):3737–3749. doi:10.3748/wjg.v26.i26.3737
   PubMed Web of Science ®Google Scholar
• Du D, Liu C, Qin M, et al. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. Acta Pharm Sin B. 2022;12(2):558–580. doi:10.1016/j.apsb.2021.09.019
   PubMed Web of Science ®Google Scholar
• Park MJ, Kim DI, Lim SK, et al. Thioredoxin-interacting protein mediates hepatic lipogenesis and inflammation via PRMT1 and PGC-1alpha regulation in vitro and in vivo. J Hepatol. 2014;61(5):1151–1157. doi:10.1016/j.jhep.2014.06.032
   PubMed Web of Science ®Google Scholar
• Xu L, Huang Z, Lo TH, et al. Hepatic PRMT1 ameliorates diet-induced hepatic steatosis via induction of PGC1α. Theranostics. 2022;12(6):2502–2518. doi:10.7150/thno.63824
   PubMed Web of Science ®Google Scholar
• Luo Y, Wang H, Liu B, Wei J. Fatty acid metabolism and cancer immunotherapy. Curr Oncol Rep. 2022;24(5):659–670. doi:10.1007/s11912-022-01223-1
   PubMed Web of Science ®Google Scholar